Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Capital Employed: 2016-2025

Historic Return on Capital Employed for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to -0.58%.

  • Intellia Therapeutics' Return on Capital Employed fell 9.00% to -0.58% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.58%, marking a year-over-year decrease of 9.00%. This contributed to the annual value of -0.47% for FY2024, which is 7.00% down from last year.
  • Intellia Therapeutics' Return on Capital Employed amounted to -0.58% in Q3 2025, which was up 3.23% from -0.60% recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Return on Capital Employed peaked at -0.23% during Q4 2021, and registered a low of -0.60% during Q2 2025.
  • Over the past 3 years, Intellia Therapeutics' median Return on Capital Employed value was -0.47% (recorded in 2024), while the average stood at -0.47%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first rose by 16bps in 2021, then fell by 19bps in 2022.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Return on Capital Employed stood at -0.23% in 2021, then dropped by 16bps to -0.39% in 2022, then dropped by 6bps to -0.45% in 2023, then decreased by 5bps to -0.50% in 2024, then declined by 9bps to -0.58% in 2025.
  • Its Return on Capital Employed stands at -0.58% for Q3 2025, versus -0.60% for Q2 2025 and -0.55% for Q1 2025.